Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE® (trofinetide)
Pipeline
Pipeline
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Hypoxic-ischemic encephalopathy
Prader-Willi Syndrome
Compassionate Use
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2026
2025
2024
2023
2022
2021
2020
2019
Older
Feb 06, 2026
First patient dosed in Neuren PMS Phase 3 trial
Feb 05, 2026
Priority Review Voucher program reauthorized by US Congress
Feb 04, 2026
Neuren receives US FDA meeting feeback for HIE and PTHS
Feb 04, 2026
Trading Halt
Feb 04, 2026
Pause in Trading
Feb 03, 2026
Acadia provides update on EU regulatory submission
Jan 19, 2026
Response to ASX Aware Letter
Jan 14, 2026
DAYBUE net sales projected to reach approx US$700m in 2028
Jan 07, 2026
NNZ-2591 PMS Phase 2 trial published in Neurology Genetics
1
